Pooled-peptide epitope mapping strategies are efficient and highly sensitive: An evaluation of methods for identifying human T cell epitope specificities in large-scale HIV vaccine efficacy trials

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Fiore Gartland, Andrew ^a   Manso, Bryce A ^a   Friedrich, David P ^a   Gabriel, Erin E ^b   Finak, Greg ^a   Moodie, Zoe ^a   Hertz, Tomer ^c   De Rosa, Stephen C ^a   Frahm, Nicole ^a   Gilbert, Peter B ^a   McElrath, M Juliana ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; PLACEBO;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERFERON GAMMA RELEASE ASSAY; MEASUREMENT ACCURACY; MULTICENTER STUDY (TOPIC); PEPTIDE ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); CYTOLOGY; DOUBLE BLIND PROCEDURE; FEMALE; IMMUNOLOGY; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; ADULT; AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84959432907     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147812     Document Type: Article

References (62)

1. Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell. 2006; 124: 677-81. doi: 10.1016/j.cell.2006.02.005 PMID: 16497577
2. Moodie Z, Rossini A, Hudgens MG, Gilbert PB, Self SG, Russell ND. Statistical evaluation of HIV vaccines in early clinical trials. Contemp Clin Trials. 2006; 27: 147-60. doi: 10.1016/j.cct.2005.11.008 PMID: 16426900
3. Herr W, Schneider J, Lohse AW, Meyer Zum Büschenfelde KH, Wölfel T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods. 1996; 191: 131-142. PMID: 8666832
4. Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods. 1997; 210: 167-174. PMID: 9520299
5. Horton H, Russell N, Moore E, Frank I, Baydo R, Havenar-Daughton C, et al. Correlation between interferon-gamma secretion and cytotoxicity, in virus-specific memory T cells. J Infect Dis. 2004; 190: 1692-6. doi: 10.1086/424490 PMID: 15478077
6. Keating SM, Bejon P, Berthoud T, Vuola JM, Todryk S, Webster DP, et al. Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria. J Immunol. 2005; 175: 5675-5680. doi: 10.4049/jimmunol.175.9.5675 PMID: 16237057
7. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009; 200: 337-46. doi: 10.1086/600120 PMID: 19569965
8. Reece WHH, Pinder M, Gothard PK, Milligan P, Bojang K, Doherty T, et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med. 2004; 10: 406-10. doi: 10.1038/nm1009 PMID: 15034567
9. Forrest BD, Pride MW, Dunning AJ, Capeding MRZ, Chotpitayasunondh T, Tam JS, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol. 2008; 15: 1042-53. doi: 10.1128/CVI.00397-07 PMID: 18448618
10. Yang S-H, Lee C-G, Park S-H, Im S-J, Kim Y-M, Son J-M, et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther. 2006; 13: 1110-7. doi: 10.1038/sj.gt.3302751 PMID: 16525482
11. Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, Horton H, et al. Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. J Infect Dis. 2013; 208: 1231-9. doi: 10.1093/infdis/jit322 PMID: 23878319
12. Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods. 2003; 283: 141-153. PMID: 14659906
13. Anthony D, Lehman P. T-cell epitope mapping using the ELISPOT approach. Methods. 2003; 29: 260-269. PMID: 12725791
14. Gill DK, Huang Y, Levine GL, Sambor A, Carter DK, Sato A, et al. Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories. PLoS One. 2010; 5: 10.
15. Mwau M, McMichael AJ, Hanke T. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses. 2002; 18: 611-8. doi: 10.1089/088922202760019301 PMID: 12079556
16. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis. 2003; 187: 226-42. doi: 10.1086/367702 PMID: 12552447
17. Hudgens MG, Self SG, Chiu Y-L, Russell ND, Horton H, McElrath MJ. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods. 2006; 288: 121-132.
18. Finak G, McDavid A, Chattopadhyay P, Rosa SDE, Roederer M, Gottardo R. Mixture Models for Single-Cell Assays with Application to Vaccine Studies. Biostatistics. 2013; 1-10.
19. Moodie Z, Huang Y, Gu L, Hural J, Self SG. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods. 2006; 315: 121-32. PMID: 16959262
20. Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother. 2010; 59: 1489-501. doi: 10.1007/s00262-010-0875-4 PMID: 20549207
21. Moodie Z, Price L, Janetzki S, Britten CM. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol. 2012; 792: 185-96. doi: 10.1007/978-1-61779-325-7-15 PMID: 21956511
22. Hudgens MG, Self SG, Chiu Y-L, Russell ND, Horton H, McElrath MJ. Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials. J Immunol Methods. 2004; 288: 19-34. PMID: 15183082
23. Carlson JM, Listgarten J, Pfeifer N, Tan V, Kadie C, Walker BD, et al. Widespread impact of HLA restriction on immune control and escape pathways of HIV-1. J Virol. 2012; 86: 5230-43. doi: 10.1128/JVI.06728-11 PMID: 22379086
24. Kaslow R, Carrington M, Apple R, Park L. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med. 1996; Available: http://www.nature.com/nm/journal/v2/n4/abs/nm0496-405.html.
25. Saah A, Hoover D, Weng S, Carrington M. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Aids. 1998; 2107-2113. Available: http://journals.lww.com/aidsonline/Abstract/1998/16000/Association-of-HLA-profiles-with-early-plasma.5.aspx. PMID: 9833851
26. Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, Ndung'u T, et al. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J Virol. 2010; 84: 9879-88. doi: 10.1128/JVI.00320-10 PMID: 20660184
27. Shea PR, Shianna K V, Carrington M, Goldstein DB. Host Genetics of HIV Acquisition and Viral Control. Annu Rev Med. 2012; 1-15. doi: 10.1146/annurev-med-052511-135400
28. McMichael A, Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol. 2002; 2: 283-91. doi: 10.1038/nri779 PMID: 12001999
29. Rerks-Ngarm S, Pitisuttithum P. Vaccination with ALVAC and ADISVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med. 2009; 361: 2209-2220. doi: 10.1056/NEJMoa0908492 PMID: 19843557
30. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008; 372: 1894-905. doi: 10.1016/S0140-6736(08)61592-5 PMID: 19012957
31. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013; 369: 2083-92. doi: 10.1056/NEJMoa1310566 PMID: 24099601
32. Kong W-P, Wu L, Wallstrom TC, Fischer W, Yang Z-Y, Ko S-Y, et al. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol. 2009; 83: 2201-15. doi: 10.1128/JVI.02256-08 PMID: 19109395
33. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. Elsevier Inc.; 2010; 33: 542-54. doi: 10.1016/j.immuni.2010.09.011
34. Horton H, Frank I, Baydo R, Jalbert E, Penn J, Wilson S, et al. Preservation of T Cell Proliferation Restricted by Protective HLA Alleles Is Critical for Immune Control of HIV-1 Infection. J Immunol. 2006; 177: 7406-7415. doi: 10.4049/jimmunol.177.10.7406 PMID: 17082660
35. Draenert R, Verrill CL, Tang Y, Allen TM, Wurcel AG, Boczanowski M, et al. Persistent Recognition of Autologous Virus by High-Avidity CD8 T Cells in Chronic, Progressive Human Immunodeficiency Virus Type 1 Infection Persistent Recognition of Autologous Virus by High-Avidity CD8 T Cells in Chronic, Progressive Human Immunodefic. J Virol. 2004;
36. Honeyborne I, Prendergast A, Pereyra F, Leslie A, Crawford H, Payne R, et al. Control of human immunodeficiency virus type 1 is associated with HLA-B∗13 and targeting of multiple gag-specific CD8+ Tcell epitopes. J Virol. 2007; 81: 3667-72. doi: 10.1128/JVI.02689-06 PMID: 17251285
37. Crawford H, Prado JG, Leslie A, Hué S, Honeyborne I, Reddy S, et al. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B∗5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J Virol. 2007; 81: 8346-51. doi: 10.1128/JVI.00465-07 PMID: 17507468
38. Yu XG, Lichterfeld M, Chetty S, Williams KL, Mui SK, Miura T, et al. Mutually exclusive T-cell receptor induction and differential susceptibility to human immunodeficiency virus type 1 mutational escape associated with a two-amino-acid difference between HLA class I subtypes. J Virol. 2007; 81: 1619-31. doi: 10.1128/JVI.01580-06 PMID: 17121793
39. Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, McElrath JM, et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine. 2006; 24: 6893-904. PMID: 16890329
40. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med. 2007; 13: 100-6. doi: 10.1038/nm1461 PMID: 17187074
41. Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, et al. Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. Mol Ther. 2014; 22: 464-475. doi: 10.1038/mt.2013.248 PMID: 24166483
42. Hudgens M, Hae-Young K. Optimal configuration of a square array group testing algorithm. Commun Stat Theory Methods. 2011; 40: 436-448. PMID: 21218195
43. Lendle SD, Hudgens MG, Qaqish BF. Group testing for case identification with correlated responses. Biometrics. 2012; 68: 532-40. doi: 10.1111/j.1541-0420.2011.01674.x PMID: 21950447
44. Precopio ML, Butterfield TR, Casazza JP, Little SJ, Richman DD, Koup RA, et al. Optimizing peptide matrices for identifying T-cell antigens. Cytometry A. 2008; 73: 1071-8. doi: 10.1002/cyto.a.20646 PMID: 18781655
45. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Johnston MN, et al. Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1) -Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load Comprehensive Epitope A. 2003; 1: 2081-2092.
46. Roederer M, Koup RA. Optimized determination of T cell epitope responses. J Immunol Methods. 2003; 274: 221-228. PMID: 12609547
47. Buchbinder SP, Mehrotra D V, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008; 372: 1881-93. doi: 10.1016/S0140-6736(08)61591-3 PMID: 19012954
48. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest. 2012; 122: 359-67. doi: 10.1172/JCI60202 PMID: 22201684
49. Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S, et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One. 2007; 2: e796. doi: 10.1371/journal.pone.0000796 PMID: 17726526
50. Moutaftsi M, Peters B, Pasquetto V, Tscharke DC, Sidney J, Bui H-H, et al. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol. 2006; 24: 817-9. doi: 10.1038/nbt1215 PMID: 16767078
51. Erup Larsen M, Kloverpris H, Stryhn A, Koofhethile CK, Sims S, Ndung'u T, et al. HLArestrictor-A tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics. 2011; 63: 43-55. doi: 10.1007/s00251-010-0493-5 PMID: 21079948
52. Bihl FK, Loggi E, Chisholm J V, Hewitt HS, Henry LM, Linde C, et al. Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti-CD3 mAb T-cell expansion and "Recycle Spot." J Transl Med. 2005; 3: 20. doi: 10.1186/1479-5876-3-20 PMID: 15888204
53. Frahm N, Korber B, Adams C, Szinger J, Addo M, Feeney M, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol. 2004; 78: 2187-2200. PMID: 14963115
54. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007; 13: 46-53. doi: 10.1038/nm1520 PMID: 17173051
55. Masemola A, Mashishi T, Khoury G, Mokgotho P, Vardas E, Colvin M, et al. Hierarchical Targeting of Subtype C Human Immunodeficiency Virus Type 1 Proteins by CD8 + T Cells: Correlation with Viral Load Hierarchical Targeting of Subtype C Human Immunodeficiency Virus Type 1 Proteins by CD8 T Cells: Correlation with Viral Load. 2004;
56. Li F, Finnefrock AC, Dubey SA, Korber BTM, Szinger J, Cole S, et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One. 2011; 6: e20479. doi: 10.1371/journal.pone.0020479 PMID: 21695251
57. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol. 2012; 188: 5166-76. doi: 10.4049/jimmunol. 1102756 PMID: 22529301
58. Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS, S: a review of the available data. Malar J. 2009; 8: 312. doi: 10.1186/1475-2875-8-312 PMID: 20042088
59. van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, Bang P, et al. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine. 2011; 29: 2100-9. doi: 10.1016/j.vaccine.2010.12.135 PMID: 21256189
60. Huygen K. The Immunodominant T-Cell Epitopes of the Mycolyl-Transferases of the Antigen 85 Complex of M. tuberculosis. Front Immunol. 2014; 5: 321. doi: 10.3389/fimmu.2014.00321 PMID: 25071781
61. Draenert R, Brander C, Xu G, Altfeld M. Impact of intrapeptide epitope location on CD8 T cell recognition: implications for design of overlapping peptide panels. Aids. 2004;
62. Boulet S, Ndongala ML, Peretz Y, Boisvert M-P, Boulassel M-R, Tremblay C, et al. A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses. J Immunol Methods. 2007; 320: 18-29. PMID: 17222422